Ozempic Tracker App
Track Your Semaglutide Protocol
Ozempic (semaglutide 0.25–2 mg weekly) is an FDA-approved GLP-1 receptor agonist for type 2 diabetes that also produces clinically significant weight loss. The SUSTAIN-6 and STEP trials confirmed both glycaemic and cardiometabolic benefits. Shotlee is the free app for logging every weekly injection, tracking your weight trend, and monitoring side effects throughout your dose escalation.
What Is Ozempic (Semaglutide)?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved in December 2017 for the treatment of type 2 diabetes in adults. It works by mimicking the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and activating hypothalamic satiety centres to reduce appetite.
Ozempic is administered as a once-weekly subcutaneous injection starting at 0.25 mg for tolerability, escalating to 0.5 mg, 1 mg, and up to 2 mg as needed. While approved for T2D, Ozempic is widely recognised for producing substantial weight loss — the same molecule at 2.4 mg weekly was approved as Wegovy for obesity. The SUSTAIN-6 cardiovascular outcomes trial demonstrated a 26% reduction in MACE in high-CV-risk T2D patients.
Ozempic Dose Escalation Schedule
Starting dose to build GI tolerance. Not a therapeutic glycaemic dose — this is a tolerability step.
First therapeutic maintenance dose. Adequate glycaemic control achieved here for many patients.
Standard maintenance dose for enhanced HbA1c reduction and weight loss effect.
Maximum approved dose for additional glycaemic and weight benefit. SUSTAIN-10 showed superior HbA1c at 2 mg.
What to Track in Shotlee
Clinical Trial Results (SUSTAIN & STEP Programs)
How to Track Your Ozempic Protocol
Ozempic vs Wegovy: Key Differences
| Feature | Ozempic | Wegovy |
|---|---|---|
| Approved indication | Type 2 diabetes | Obesity / weight managementBest |
| Maximum dose | 2 mg/week | 2.4 mg/week |
| Active ingredient | Semaglutide | Semaglutide |
| Dosing frequency | Once weekly | Once weekly |
| Key trial | SUSTAIN-6 (CV outcomes) | STEP-1 (weight loss) |
| Insurance coverage | T2D indication | Obesity criteria |
Protocol FAQs
Log each weekly injection in Shotlee with the dose (0.25–2 mg), injection site, and any side effects. Shotlee keeps a complete timeline of your protocol history and reminds you when your next weekly dose is due.
Yes. Shotlee supports tracking multiple medications simultaneously, including combination protocols such as Ozempic with metformin, insulin, or other diabetes medications.
Both contain semaglutide. Ozempic (max 2 mg) is approved for type 2 diabetes. Wegovy (max 2.4 mg) is approved for obesity/weight management. Shotlee tracks both medications with full dose support.
Most patients see meaningful weight loss beginning at week 8–12. Maximum effect in the STEP-1 trial occurred around week 68 with 14.9% mean weight loss. Track weekly in Shotlee to see your personal response curve.
Yes. Log your pen lot number, start date, and injection site. Shotlee helps you rotate between abdomen, thigh, and upper arm to prevent lipodystrophy.
Track Your Ozempic Protocol in Shotlee
Free dose logs, weekly weight trends, side effect tracking — all in one place.
📚References & sources
Latest on Semaglutide
Alli Weight Loss Pill: FDA Flags Serious Kidney Risks
The Food and Drug Administration (FDA) has issued a new warning regarding potential serious kidney complications associated with Alli, the sole over-the-counter weight loss medication available in the United States. The drug's label has been updated to reflect these risks, urging caution for consumers.
8 min read
Beyond Weight Loss: How GLP-1s Impact Your Blood Pressure
GLP-1 receptor agonists, known for their role in diabetes and weight management, are increasingly recognized for their broader health benefits, including effects on blood pressure. This article delves into how these medications work, their impact on cardiovascular health, and whether they are safe for individuals with hypertension.
8 min read
Wegovy Pill Arrives in the UK: A New Era for Weight Management?
The UK has officially approved a pill version of the popular Wegovy weight-loss drug, marking a significant advancement in accessible obesity treatment. This development offers a convenient alternative to weekly injections for many.
6 min read